Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Zepbound is a GLP-1 agonist containing tirzepatide ... and 3.2% (with diabetes). Starting dose: 2.5 mg weekly, increasing to 5 mg after 4 weeks. Doses may continue to increase to a maximum ...

while Zepbound pens are available in all doses. A doctor will recommend which dose a person should start with. Generally, Zepbound starter doses will be the lowest dose available. You will then ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...